Atrial Fibrillation: Important Impact on TAVI

Original Title: Atrial Fibrillation Is Associated With Increased Mortality in Patients Undergoing Transcatheter Aortic Valve Replacement: Insights From the Placement of Aortic Transcatheter Valve (PARTNER) Trial. Reference: Angelo B. Biviano et al. Circ Cardiovasc Interv. 2016 Jan;9(1):e002766. Courtesy of Dr. Carlos Fava. The conversion to atrial fibrillation (AF) in the context of transcatheter aortic valve replacement<a href="https://solaci.org/en/2016/03/04/atrial-fibrillation-important-impact-on-tavi/" title="Read more" >...</a>

Comparing Computed Tomography vs. Angiography to Assess Transfemoral Access for TAVI

Original Title: Transfemoral Access Assessment for Transcatheter Aortic Valve Replacement Evidence Based Application of Computed Tomography over Invasive Angiography. Reference: Circ Cardiovas Imaging 2015 DOI:10.1161/CIRCIMAGING.114.0011995. Courtesy of Dr. Guillermo Migliaro Transfemoral access for TAVI was introduced in 2006 and is considered first choice. Vascular complications (VCs) are important events that correlate to increased mortality. According to the<a href="https://solaci.org/en/2016/01/18/comparing-computed-tomography-vs-angiography-to-assess-transfemoral-access-for-tavi/" title="Read more" >...</a>

TAVI: Mobility Predicts Outcomes

Original Title: Poor Mobility Predicts Adverse Outcomes Better Than Other Frailty Indices in Patients Undergoing Transcatheter Aortic Valve Implantation. Reference: James Cockburn, et al. Catheterization and Cardiovascular Intervention 2015;86:1271-1277 Courtesy of Dr. Carlos Fava Interventional Cardiologist Favaloro Foudation – Buenos Aires There is a group of high risk patients that are also fragile, and there is<a href="https://solaci.org/en/2015/12/17/tavi-mobility-predicts-outcomes/" title="Read more" >...</a>

TAVI in patients older than 90: similar outcomes to those obtained in younger patients

Original title: Comparison of Outcomes of Transcathether Aortic Valve Implantation in Patients ≥90 Years Versus <90 Years. Reference: Yigal Abramowitz, et al. Am J Cardiol 2015;116:1110-1115. More and more 90 year old patients require transcatheter aortic valve replacement (TAVI); however, its benefits have not been studied in this particular population. This study enrolled 734 patients<a href="https://solaci.org/en/2015/11/16/tavi-in-patients-older-than-90-similar-outcomes-to-those-obtained-in-younger-patients/" title="Read more" >...</a>

SAPIENS 3: Favorable outcomes with TAVI in intermediate risk patients

Transcatheter aortic valve replacement is a safe and effective alternative to surgery in patients with severe aortic stenosis and high surgical risk as the 5-year results of PARTNER 1 Alternate showed. The aim of this study was to evaluate the result of the Edwards Sapien 3 valve in patients with severe aortic stenosis and intermediate<a href="https://solaci.org/en/2015/06/24/sapiens-3-favorable-outcomes-with-tavi-in-intermediate-risk-patients/" title="Read more" >...</a>

TAVR é um procedimento tão seguro e eficaz quanto a substituição cirúrgica num seguimento de dois anos em pacientes de menor risco.

Fundamentos e  Objetivos: A substituição da válvula aórtica via transcateter (TAVR) é uma opção em determinados pacientes cirúrgicos de alto risco com estenose da válvula aórtica grave. Desconhecemos se a TAVR pode ser introduzida com segurança para os pacientes de baixo risco. O estudo NOTION (Nordic Aortic Valve Intervention Trial) é um ensaio clínico randomizado<a href="https://solaci.org/en/2015/06/24/tavr-e-um-procedimento-tao-seguro-e-eficaz-quanto-a-substituicao-cirurgica-num-seguimento-de-dois-anos-em-pacientes-de-menor-risco-2/" title="Read more" >...</a>

NOTION: TAVR in low-risk patients

The aim of this study was to compare the results of transcatheter aortic valve replacement (TAVR) versus surgery in unselected patients with severe degenerative aortic stenosis. Patients were randomized 1:1 to TAVR (n = 145) or surgical replacement (n = 135). Those of TAVR group received Medtronic CoreValve self-expanding valve. The femoral access was used<a href="https://solaci.org/en/2015/06/24/notion-tavr-in-low-risk-patients/" title="Read more" >...</a>

PARTNER to 5 years. TAVR is an effective alternative to surgery in high risk patients

This study included 699 patients with severe aortic stenosis and high surgical risk of whom 348 received transcatheter aortic valve replacement (TAVR) and 351 received surgery. Previous reports of the results to one, two and three years and this work published simultaneously in Lancet reports the final follow-up at 5 years. The mortality at follow-up<a href="https://solaci.org/en/2015/06/24/partner-to-5-years-tavr-is-an-effective-alternative-to-surgery-in-high-risk-patients/" title="Read more" >...</a>

UK TAVI Registry: Long-term results of TAVI in the UK

This record has been created in order to evaluate the results of percutaneous aortic valve replacement in the UK and currently includes more than 4500 patients with 100% follow-up for mortality. The 3-year mortality was 61.6 % beyond the device or path. Atrial fibrillation, renal failure, chronic obstructive pulmonary disease and a EuroSCORE > 18.5<a href="https://solaci.org/en/2015/06/24/uk-tavi-registry-long-term-results-of-tavi-in-the-uk/" title="Read more" >...</a>

PARTNER cohort A at three years, the benefit continues

The PARTNER Cohort A randomized 699 elderly patients, (mean age 84.1), with severe aortic stenosis for TAVI or conventional surgery in 26 centers. The group of patients who received TAVI was divided into two groups: trans-femoral procedure, (244 patients), or trans-apical procedure, (104 patients). After one year mortality was similar but stroke and transient ischemic<a href="https://solaci.org/en/2015/06/24/partner-cohort-a-at-three-years-the-benefit-continues/" title="Read more" >...</a>